查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002818

HIV臨床試驗市場：按藥物類別、試驗階段、最終用戶、給藥途徑、分銷管道和患者年齡層分類－2026年至2032年全球市場預測

HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，愛滋病臨床試驗市場價值將達到 15.5 億美元，到 2026 年將成長到 21.6 億美元，到 2032 年將達到 176 億美元，複合年成長率為 41.45%。

主要市場統計數據
基準年 2025 15.5億美元
預計年份：2026年 21.6億美元
預測年份 2032 176億美元
複合年成長率 (%) 41.45%

本文簡要概述了愛滋病臨床試驗的現狀，重點在於創新促進因素、營運限制以及相關人員面臨的策略挑戰。

全球開發安全、有效且可及的愛滋病治療方法的努力已進入一個需要加速創新和進行務實重新評估的階段。抗病毒機制的科學進步、試驗設計的改進以及對以患者為中心的治療結果日益重視，都提高了人們對營運效率和公平獲取的期望。同時，申辦方、研究人員和試驗中心面臨不斷變化的監管要求和複雜的供應鏈，需要進行適應性規劃。

科學突破、監管現代化和數位轉型如何重新定義愛滋病臨床試驗的典範和營運重點。

在科學突破、數位轉型和政策演變的推動下，愛滋病臨床試驗正在經歷一場變革。分子病毒學和新型藥物療法的進步正在拓展治療選擇，而適應性試驗設計和分散式要素的引入則改變了受試者的招募、監測和留存方式。這些變革正在解決傳統的瓶頸問題，並為更有效率地檢驗更具針對性的假設創造機會。同時，數位化終點、遠端監測平台和電子資料收集（EDC）的採用，使得更持續、以患者為中心的評估成為可能，從而減輕了臨床試驗中心的負擔。

本研究評估了美國關稅措施和相關貿易政策轉變如何重塑愛滋病臨床試驗的供應鏈、營運成本和國際合作動態。

美國近期實施的關稅措施及相關貿易政策調整，正對愛滋病臨床試驗生態系統產生顯著的間接影響，主要體現在改變上游成本和物流動態，而非直接改變科學典範。對活性成分、專用實驗室設備和必要包裝組件徵收關稅，可能會延長臨床實驗藥物生產和臨床供應鏈的採購前置作業時間，並增加常規採購成本。因此，臨床試驗贊助者和契約製造生產商越來越重視雙重採購、庫存緩衝以及與報關行更緊密的合作，以確保臨床實驗進度。

從細分觀點治療領域、試驗階段、醫療保健服務環境、給藥途徑、通路和病患年齡如何相互交織，進而影響策略性試驗選擇。

細分分析揭示了不同治療領域、試驗階段、臨床環境、給藥途徑、通路和患者族群的策略意義各不相同。治療研發的優先順序因藥物類別而異。病毒進入抑制劑，例如恩韋地肽和馬拉維羅克，主要針對早期病毒進入機制，通常需要腸外給藥。整合酶鏈轉移抑制劑，例如比克替拉韋、多替拉韋、埃爾維特格拉韋和拉替拉韋，通常用於簡化給藥方案，但需要密切監測藥物交互作用和抗藥性。非核苷類逆轉錄酶抑制劑，例如依非韋倫、依曲韋林、奈韋拉平和利匹韋林，在試驗設計中體現了其獨特的安全性和中樞神經系統（CNS）耐受性特徵，而核苷類逆轉錄酶抑制劑，例如恩曲他濱、拉米夫定、替諾福韋和齊多夫定，仍然是骨幹策略的核心。對於阿扎那韋、達蘆那韋、福沙那韋和洛匹那韋等蛋白酶抑制劑，有必要評估可能影響終點選擇的代謝和藥物依從性因素。

我們在美洲、歐洲、中東和非洲以及亞太地區的營運和監管專業知識將有助於選擇最佳臨床實驗地點並制定實施策略。

區域趨勢對試驗設計、實施和監管合作有顯著影響。儘管美洲地區完善的研究基礎設施和成熟的法規結構使得許多申辦方能夠快速啟動試驗，但該地區地域的多樣性要求對試驗地點進行仔細的可行性評估，以確保受試者招募具有代表性並實現公平的試驗機會。北美臨床試驗中心通常主導早期創新，而拉丁美洲各地的試驗中心則在真實臨床環境中驗證療效和擴大受試者多樣性方面發揮著至關重要的作用。

深入了解影響 HIV 臨床開發中卓越營運和轉換動力的有影響力的贊助商、合作模式和服務供應商。

參與愛滋病臨床開發的機構競爭格局複雜多樣，既有成熟的製藥公司，也有專注於生物製藥開發的專業公司、合約研究組織（CRO）、學術聯盟，以及提供數據、物流和病人參與等服務供應商。老字型大小企業憑藉其豐富的臨床經驗和全球開發網路，持續推動大規模的核准申報項目。同時，新興企業和生技創新者則致力於透過差異化的作用機制和目標患者群體，打造獨特的價值提案。

為贊助商和營運經理提供實用建議，以增強 HIV 臨床試驗中的供應彈性、監管合規性、參與者參與度和共同研究模式。

產業領導者應優先採取一系列切實可行的措施，以增強韌性、加快證據產生並確保公平取得。首先，投資於多元化的供應商網路和合約機制，以確保臨床實驗藥物和關鍵實驗室試劑的持續供應。其次，謹慎地融入分散式試驗的要素，以減輕受試者的負擔，同時保持嚴格的監測控制和檢驗的遠端資料收集。

採用透明的、基於三角測量的調查方法，結合一手訪談、文獻綜述、操作案例研究和嚴​​格檢驗，以確保可靠的測試資訊。

本報告的分析是基於三角測量研究方法，該方法結合了對關鍵意見領袖 (KOL) 的訪談、對同行評審文獻和公開監管文件的二手研究，以及對近期 HIV 臨床試驗項目運作的案例研究。一級資訊來源包括對臨床研究人員、試驗管理人員、供應鏈經理和患者諮詢委員會代表的結構化訪談，以了解實際挑戰和新興最佳實踐。二級資訊來源包括臨床試驗報告、監管指導文件和調查方法文獻，這些文獻提供了有關試驗設計、安全監測和終點選擇的見解。

策略性地整合營運需求、協作方法和以參與者為中心的設計，指導 HIV 臨床開發中的有效決策。

整合科學、營運和政策觀點，有助於為參與愛滋病臨床研發的機構制定一套一致的優先事項。目前最迫切的挑戰在於如何將創新的試驗設計與實際操作相結合——即利用適應性和分散性要素來提高效率，同時確保資料流的檢驗和獲得監管部門的核准。同樣重要的是，要將供應鏈韌性和供應商管治視為試驗可行性的關鍵組成部分，而非事後補救措施，因為已有研究表明，這些因素可能會延遲受試者招募或干擾檢體處理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：愛滋病臨床試驗市場：依藥物類別分類

  • 入侵抑制劑
    • 恩夫維爾奇德
    • 馬拉威羅克
  • 整合酶鏈轉移抑制劑
    • 比克替拉韋
    • 多替拉韋
    • 埃爾維特格拉維爾
    • 拉特格拉維爾
  • 非核苷類逆轉錄酶抑制劑
    • 依非韋倫
    • 依福西林
    • 奈韋拉平
    • 利匹韋林
  • 核苷類逆轉錄酶抑制劑
    • 恩曲他濱
    • 拉米夫定
    • 替諾福韋
    • 齊多夫定
  • 蛋白酶抑制劑
    • 阿扎那韋
    • 達蘆那韋
    • 福斯帕奈韋
    • 洛匹那韋

第9章 HIV臨床試驗市場：按階段分類的臨床試驗

  • 第一階段
  • 第二階段
    • 第二階段a
    • IIb期
  • 第三階段
  • 第四階段

第10章：愛滋病臨床試驗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構
    • 學術機構
    • 合約研究組織（CTA）

第11章 HIV臨床試驗市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮

第12章 HIV臨床試驗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第13章：依病患年齡層別分類的愛滋病臨床試驗市場

  • 成人版
  • 老年人
  • 兒童

第14章 HIV臨床試驗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 HIV臨床試驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 愛滋病臨床試驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國愛滋病臨床試驗市場

第18章：中國愛滋病臨床試驗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market was valued at USD 1.55 billion in 2025 and is projected to grow to USD 2.16 billion in 2026, with a CAGR of 41.45%, reaching USD 17.60 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.55 billion
Estimated Year [2026] USD 2.16 billion
Forecast Year [2032] USD 17.60 billion
CAGR (%) 41.45%

A concise framing of the contemporary HIV clinical trials landscape highlighting innovation drivers, operational constraints, and strategic imperatives for stakeholders

The global effort to develop safe, effective, and accessible HIV therapies has entered a period of intensified innovation and practical recalibration. Scientific advances in antiviral mechanisms, improvements in trial design, and an increasing emphasis on patient-centered outcomes have combined with heightened expectations for operational efficiency and equitable access. Simultaneously, sponsors, investigators, and trial sites face evolving regulatory expectations and supply-chain complexities that require adaptive planning.

This executive summary provides decision-makers with a focused synthesis of the forces shaping contemporary HIV clinical trials. It identifies core scientific and operational drivers, highlights systemic risks that can impede development timelines, and surfaces practical levers stakeholders can use to strengthen program resilience. By integrating clinical, logistical, and policy perspectives, the summary gives leaders a clear vantage point from which to prioritize investments, refine partnerships, and accelerate translational pipelines while maintaining ethical and regulatory rigor.

Throughout, the analysis emphasizes actionable clarity: where to allocate resources to improve recruitment and retention, how to anticipate and manage cross-border operational friction, and which collaborative models have demonstrated the greatest potential to shorten time to reliable evidence without compromising safety or data integrity.

How scientific breakthroughs, regulatory modernization, and digital transformation are collectively redefining HIV clinical trial paradigms and operational priorities

HIV clinical trials are being reshaped by a conjunction of scientific breakthroughs, digital transformation, and policy evolution. Advances in molecular virology and novel drug modalities have expanded the therapeutic toolkit, while adaptive trial designs and decentralized elements have begun to change how participants are recruited, monitored, and retained. These shifts reduce conventional bottlenecks and create opportunities to test more targeted hypotheses with greater efficiency. At the same time, the adoption of digital endpoints, remote monitoring platforms, and electronic source data capture is enabling more continuous, patient-centric assessments and reducing site burden.

Regulatory agencies worldwide are also signaling increased openness to innovative approaches, particularly when studies are designed with clear risk mitigation and robust data quality controls. This regulatory receptivity, however, comes with heightened expectations around data provenance, device validation, and participant protections, which require early dialog and alignment. Moreover, the emergence of public-private partnerships and academic-industry consortia is accelerating translational research while raising important questions about data sharing, IP stewardship, and equitable distribution of benefits.

As these transformative forces coalesce, stakeholders must balance speed with rigor, and innovation with access. Pragmatic integration of new technologies, coupled with deliberate stakeholder engagement and strengthened supply resilience, will determine which programs realize their potential to deliver meaningful clinical advances.

Assessing how United States tariff measures and related trade policy shifts are reshaping HIV clinical trial supply chains, operational costs, and international collaboration dynamics

Recent tariff measures implemented by the United States and related trade policy shifts have had a pronounced indirect effect on the HIV clinical trials ecosystem, primarily by altering upstream cost and logistics dynamics without directly changing scientific paradigms. Tariffs on active pharmaceutical ingredients, specialized laboratory equipment, and essential packaging components can increase procurement lead times and elevate routine sourcing costs for investigational product manufacturing and clinical supply chains. In turn, sponsors and contract manufacturers have increasingly prioritized dual sourcing, inventory buffering, and closer coordination with customs brokers to preserve study timelines.

Beyond material costs, tariffs can complicate cross-border collaborations that underpin global trial networks. Research sites that rely on imported diagnostic reagents or cold-chain logistics may experience episodic shortages or face unexpected customs delays, which can disrupt specimen handling and compromise data integrity if not proactively managed. Additionally, tariff-driven cost pressure can intensify negotiations around pricing for ancillary services, leading some sponsors to re-evaluate the geographic distribution of laboratory services, central lab consolidation, or greater reliance on regional suppliers.

Importantly, tariff effects intersect with policy and operational responses: regulatory flexibility for alternative supplier validation, accelerated import permits for clinical supplies, and contractual clauses that allocate risk among sponsors and providers. Looking ahead, industry leaders should anticipate that tariff volatility will remain a factor in supply planning and should incorporate scenario-based risk assessments, strengthened supplier governance, and enhanced visibility into end-to-end logistics to shield clinical programs from avoidable disruption.

Segmentation-driven perspectives on how therapeutic class, trial phase, care setting, administration route, distribution channel, and patient age intersect to shape strategic trial choices

Segmentation analysis reveals differentiated strategic implications across therapeutic categories, trial stages, care settings, administration routes, distribution channels, and patient demographics. When classified by drug class, therapeutic development priorities vary: Entry Inhibitors such as enfuvirtide and maraviroc focus on targeting initial viral entry mechanisms and often require parenteral administration strategies, whereas Integrase Strand Transfer Inhibitors including bictegravir, dolutegravir, elvitegravir, and raltegravir frequently underpin regimen simplification efforts and demand attention to drug-drug interactions and resistance surveillance. Non-Nucleoside Reverse Transcriptase Inhibitors like efavirenz, etravirine, nevirapine, and rilpivirine bring their own safety and CNS tolerability profiles to trial design, while Nucleoside Reverse Transcriptase Inhibitors-emtricitabine, lamivudine, tenofovir, and zidovudine-remain central to backbone strategies. Protease Inhibitors such as atazanavir, darunavir, fosamprenavir, and lopinavir require evaluation of metabolic and adherence considerations that influence endpoint selection.

By trial phase, the emphasis shifts from safety and proof-of-concept in Phase I and Phase IIa/IIb to broader efficacy and comparative endpoints in Phase III and real-world safety in Phase IV. Trial phase influences sample size, operational complexity, and monitoring intensity, which in turn affects site selection and patient engagement strategies. End-user segmentation underscores different operational models: clinics and hospitals deliver point-of-care recruitment and integrated monitoring, while research institutes, including academic centers and contract research organizations, often provide specialized expertise and centralized data oversight.

Route of administration considerations-injectable, oral, and transdermal-drive both patient acceptability and supply-chain requirements, with injectables requiring cold-chain or sterile compounding competencies and oral regimens emphasizing adherence support. Distribution channel nuances across hospital pharmacies, online pharmacies, and retail pharmacies, with retail further divided into chain and independent outlets, affect dispensing workflows and post-trial access planning. Finally, patient age groups-adult, geriatric, and pediatric-necessitate tailored safety monitoring, consent processes, and endpoint selection to ensure that trials generate clinically actionable evidence for each population segment.

Regional operational and regulatory insights across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform optimized trial site selection and execution strategies

Regional dynamics exert a strong influence on trial design, operational execution, and regulatory engagement. In the Americas, established research infrastructures and mature regulatory frameworks facilitate rapid study start-up for many sponsors, yet geographic diversity within the region necessitates careful site feasibility assessments to ensure representative enrollment and equitable access. Clinical sites in North America often lead in early-phase innovation, while sites across Latin America play a critical role in demonstrating real-world effectiveness and expanding participant diversity.

Europe, Middle East & Africa presents a heterogeneous regulatory landscape where harmonization initiatives coexist with localized requirements. Sponsors operating across this expanse must balance the advantages of experienced academic centers and large patient pools against variable ethics review timelines and administrative processes. In many jurisdictions, investment in capacity building, standardized data-capture practices, and early regulatory dialogue proves essential to mitigate delays and maintain data quality.

Asia-Pacific combines rapidly growing clinical research capacity with variable reimbursement and regulatory pathways. The region offers opportunities for accelerated enrollment and access to diverse patient populations, but success depends on culturally adapted recruitment strategies, local investigator engagement, and robust supply-chain planning to navigate importation and site provisioning. Across all regions, aligning trial architecture with local clinical practice, engaging community stakeholders, and investing in site training and quality oversight are pivotal to generating high-integrity, generalizable evidence.

Intelligence on influential sponsors, collaborative models, and service providers that are shaping operational excellence and translational momentum in HIV clinical development

The competitive landscape of organizations involved in HIV clinical development reflects a mix of established pharmaceutical sponsors, specialist biologics developers, contract research organizations, academic consortia, and service providers focused on data, logistics, and patient engagement. Established companies continue to leverage deep clinical experience and global development networks to advance large-scale registrational programs, while emerging players and biotech innovators concentrate on differentiated mechanisms of action and targeted populations to carve niche value propositions.

Collaborative models-ranging from strategic alliances between industry and academic centers to multi-stakeholder consortia that share protocols and pooled data-have become more prominent as a way to spread risk and accelerate evidence generation. Contract research organizations and specialty service providers play a critical role in operationalizing complex trial elements such as long-acting injectable manufacturing, cold-chain management, and decentralized trial components. Technology vendors that provide validated electronic data capture, remote monitoring, and interoperable laboratory information systems are increasingly integral to ensuring data integrity and regulatory compliance.

Leadership in this ecosystem depends on integrating scientific clarity with operational excellence. Organizations that combine precise mechanistic hypotheses with robust site governance, flexible supply arrangements, and community-informed recruitment strategies will be best positioned to execute high-quality trials that deliver clinically meaningful outcomes.

Actionable recommendations for sponsors and operational leaders to enhance supply resilience, regulatory alignment, participant engagement, and collaborative research models in HIV trials

Industry leaders should prioritize a set of pragmatic, actionable measures to increase resilience, accelerate evidence generation, and ensure equitable access. First, invest in diversified supplier networks and contractual mechanisms that preserve continuity of investigational product supply and critical laboratory reagents. Second, embed decentralized trial elements judiciously to reduce participant burden while maintaining rigorous monitoring controls and validated remote data capture.

Third, engage regulators and ethics committees early and often to align on adaptive designs, biomarker endpoints, and safety monitoring frameworks; proactive engagement reduces cycles and increases the likelihood of regulatory acceptance. Fourth, design recruitment and retention strategies that are community-informed and culturally sensitive, particularly when trials span multiple regions and demographic groups. Fifth, implement data governance practices that ensure interoperability, traceability, and rapid auditability to meet both regulatory expectations and publication standards.

Finally, cultivate collaborative consortia and public-private partnerships that share noncompetitive data and infrastructure, thereby lowering barriers to entry for smaller developers and accelerating comparative effectiveness research. By integrating these actions into program planning, leaders can reduce operational risk, optimize resource allocation, and increase the probability that trials generate clinically consequential and generalizable results.

A transparent, triangulated research methodology that integrates primary interviews, literature review, operational case studies, and rigorous validation to ensure reliable trial intelligence

The analysis underpinning this report draws on a triangulated research approach that combines primary interviews with key opinion leaders, secondary review of peer-reviewed literature and public regulatory documents, and operational case studies of recent HIV trial programs. Primary inputs include structured interviews with clinical investigators, trial operations leaders, supply-chain managers, and patient-advisory representatives to capture frontline challenges and emergent best practices. Secondary sources encompass clinical study reports, regulatory guidance documents, and methodological literature that inform trial design, safety monitoring, and endpoint selection.

Analytical frameworks employed include risk mapping for supply-chain vulnerability, decision-tree modeling for site selection, and stakeholder impact matrices to prioritize mitigation strategies. Validation steps incorporated cross-checks between interview insights and documented trial outcomes, as well as iterative reviews with external subject matter experts to ensure interpretive accuracy. Quality controls comprised source verification for all cited regulatory positions and internal audit trails for interview transcripts and synthesis notes.

Limitations are acknowledged, including the dynamic nature of trade policy and regulatory guidance, which may evolve after the report's compilation. To mitigate these constraints, the methodology emphasizes transparent assumptions, scenario-based analyses, and clear delineation between observed practice and expert projection, thereby enabling readers to adapt the findings to their specific operational contexts.

A strategic synthesis that integrates operational imperatives, collaborative approaches, and participant-centered design to guide effective HIV clinical development decisions

Bringing together scientific, operational, and policy perspectives yields a coherent set of priorities for organizations engaged in HIV clinical development. The most immediate imperative is to harmonize innovative trial design with pragmatic execution: leverage adaptive and decentralized elements to increase efficiency while ensuring validated data flows and regulatory acceptability. Equally important is treating supply-chain resilience and supplier governance as integral components of trial feasibility rather than as afterthoughts, given their demonstrated capacity to delay enrollment and compromise specimen handling.

Strategically, sponsors should pursue collaborative architectures that combine the strengths of industry, academia, and specialized service providers to accelerate translational pathways and broaden access to diverse participant cohorts. Operational leaders must invest in digital and human infrastructure that supports remote monitoring, standardized laboratory practices, and culturally tailored recruitment. Finally, sustained engagement with regulators and community stakeholders will smooth the path for novel endpoints and increase public trust in trial results.

Taken together, these imperatives set a practical agenda: integrate scientific ambition with operational rigor, anticipate and mitigate supply and policy risks, and center participant needs in study design. Organizations that execute along these lines will be better positioned to deliver robust, actionable evidence that advances therapy and access for people living with HIV.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Clinical Trials Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Emtricitabine
    • 8.4.2. Lamivudine
    • 8.4.3. Tenofovir
    • 8.4.4. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. HIV Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase II
    • 9.2.1. Phase IIa
    • 9.2.2. Phase IIb
  • 9.3. Phase III
  • 9.4. Phase IV

10. HIV Clinical Trials Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Institutes
    • 10.3.2. Contract Research Organizations

11. HIV Clinical Trials Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Transdermal

12. HIV Clinical Trials Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. HIV Clinical Trials Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. HIV Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. HIV Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. HIV Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States HIV Clinical Trials Market

18. China HIV Clinical Trials Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Gilead Sciences, Inc.
  • 19.7. Johnson & Johnson
  • 19.8. Merck & Co., Inc.
  • 19.9. Moderna, Inc.
  • 19.10. Pfizer Inc.
  • 19.11. Roche Holding AG
  • 19.12. Sanofi S.A.
  • 19.13. Takeda Pharmaceutical Company Limited
  • 19.14. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. GCC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 296. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 297. GCC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 302. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DI